Spots Global Cancer Trial Database for Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis
Official Title: Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis. A Randomized Trial Comparing Two Periodicities of Ultrasonographic Surveillance: 3-month vs 6-month
Study ID: NCT00190385
Conditions
Interventions
Study Description
Brief Summary: Liver carcinoma is becoming the main complication of cirrhosis. Treatment of symptomatic or large tumors is disappointing. Regular ultrasonographic screening of small (curable) tumors is currently recommended, but the best periodicity is unknown.This randomized trial is aimed to compare 6-month (current recommendation) and 3-month ultrasonographic screenings.
Detailed Description: Patients: All consecutive patients with compensated HBV, HCV, alcohol or hemochromatosis-related cirrhosis (without any previous clinical complication including liver cancer). Randomization: factorial: ultrasonography (3-month versus 6-month); serum alfa-fetoprotein assay (none versus 6-month). End points: rate of small tumors (first main criteria); survival (second main criteria).
Eligibility
Minimum Age: 30 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hopital Jean Verdier, Paris, Ile de France, France
Contact Details
Name: Jean-Claude Trinchet, Pr, MD, PhD
Affiliation: Assistance Publique - Hôpitaux de Paris
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
